Edward G. Lorenzana

发表

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

Joshua M. Korn, Derek Y. Chiang, Tara L. Naylor, 2015, Nature Medicine.

CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer.

Oleg Mayba, Florian Gnad, Ehud Segal, 2016, The Journal of clinical investigation.

Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization.

M. P. Dillon, R. Grotzfeld, Edward G. Lorenzana, 2019, ACS medicinal chemistry letters.

Efficacy of a Novel Bi-Steric mTORC1 Inhibitor in Models of B-Cell Acute Lymphoblastic Leukemia

Mallika Singh, Edward G. Lorenzana, D. Fruman, 2021, Frontiers in Oncology.

Abstract 3790: Preclinical profile of LGX818: A potent and selective RAF kinase inhibitor

G. Caponigro, Nanxin Li, Edward G. Lorenzana, 2012 .

Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth

G. Kiss, N. Rosen, Mallika Singh, 2021, Nature Chemical Biology.

Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.

B. Weisburd, F. McCormick, M. Holderfield, 2014, Cancer research.

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models

Edward G. Lorenzana, G. Hatzivassiliou, M. Merchant, 2015, Journal of Immunotherapy for Cancer.

Characterization of a novel Raf kinase inhibitor that causes target dependent tumor regression in human melanoma xenografts expressing mutant B-Raf

Wei Zhang, Edward G. Lorenzana, Fernando Salangsang, 2006 .

CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer.

M. Yaylaoglu, C. Watanabe, Edward G. Lorenzana, 2016, The Journal of clinical investigation.